



Ain Shams University  
Faculty of Medicine

# **Sleeve Gastrectomy in Surgical Management of Morbid Obesity (Effect, Advantage and Complication)**

**Essay**

*Submitted in Partial Fulfillment for Master Degree  
In General Surgery*

**By**

**Amr Fahim Mohammad Amer**

*M.B.B.Ch.*

**Supervisors**

**Prof. Dr. Awad Hassan El-Kayal**

*Professor of General Surgery*

*Faculty of Medicine- Ain Shams University*

**Dr. Mohamed Ibrahim Hassan**

*Lecturer of General Surgery*

*Faculty of Medicine - Ain Shams University*

**Faculty of Medicine**

**Ain Shams University**

**2015**


## *Acknowledgement*

First and foremost, I would like to begin by thanking **ALLAH**, Most Strong, All Almighty, for providing me the strength and perseverance required to achieve this work.

First of all I would like to thank **Prof. Dr. Awad Hassan El-Kayal**, Professor of General Surgery, Ain Shams University, for his support and invaluable professional and scientific discussions.

I sincerely appreciate the assistance of **Dr. Mohamed Ibrahim Hassan**, Lecturer of General Surgery, Ain Shams University, who greatly contributed to the initiation of this work.

**Finally** I want to express my love and appreciation for my great family who prayed and helped me a lot in every moment of my life.



*Amr Fahim*

# Contents

List of Abbreviations .....	I
List of Figures .....	III
<b>Introduction.....</b>	<b>1</b>
<b>Aim of Work .....</b>	<b>3</b>
<b>Review of Literature .....</b>	
- Chapter (1): Definition and diagnosis .....	5
- Chapter (2): Pathophysiology and metabolic changes.....	18
- Chapter (3): Complications of obesity .....	31
- Chapter (4): Surgical management of morbid obesity.....	56
- Chapter (5): Sleeve gastrectomy in management of morbid obesity .....	91
- Chapter (6): Morbidity of surgery .....	118
- Chapter (7): Management of the morbidity of surgery ..	146
<b>Summary .....</b>	<b>175</b>
<b>References.....</b>	<b>179</b>
<b>Arabic Summary.....</b>	<b>--</b>

## ***List of Abbreviations***

<b>ACTH</b>	Adrenocorticotrophic hormone
<b>AIDS</b>	Acquired Immune Deficiency Syndrome
<b>BED</b>	Binge eating disorder
<b>BMI</b>	Body Mass Index
<b>BPD</b>	Biliopancreatic diversion
<b>BPD-DS</b>	Biliopancreatic diversion with duodenal switch
<b>CAT</b>	Computerized axial tomography
<b>CNS</b>	Central nervous system
<b>CRH</b>	Corticotrophic releasing hormone
<b>CT</b>	Computerized Tomography
<b>DVT</b>	Deep Vein Thrombosis
<b>DXA</b>	Dual energy X-ray absorptiometry
<b>ECG</b>	Electrocardiogram
<b>EWL</b>	Excess weight loss
<b>FDA</b>	U.S. Food and Drug Administration
<b>FFMI</b>	Fat – Free Mass Index
<b>FMI</b>	Fat Mass Index
<b>GE</b>	Gastro-Esophageal
<b>GERD</b>	Gastroesophageal reflux disease
<b>GH</b>	Growth Hormone
<b>GHD</b>	Growth Hormone Deficiency
<b>GHS</b>	Growth Hormone Secretagogue
<b>GLP-1</b>	Glucagon-like peptide 1
<b>I.M</b>	Intra-Muscular
<b>I.V</b>	Intra-venous
<b>IGS</b>	Implantable gastric stimulator
<b>JIB</b>	Iejunoileal bypass
<b>LAGB</b>	Laparoscopic adjustable gastric banding
<b>LDL</b>	Low- density lipoprotein
<b>LRYGB</b>	Laparoscopic Roux-en-Y gastric bypass

### ***List of Abbreviations (Cont...)***

<b>LSG</b>	Laparoscopic Sleeve Gastrectomy
<b>NJT</b>	Naso-jejunal tube
<b>NOTES</b>	Natural orifice transluminal endoscopic surgery
<b>NPY</b>	Neuropeptide Y
<b>PCOS</b>	Polycystic ovarian syndrome
<b>PE</b>	Pulmonary Embolism
<b>POD</b>	Post-operative day
<b>PVN</b>	Paraventricular nuclei
<b>RYGB</b>	Roux-en-Y gastric bypass
<b>SG</b>	Sleeve gastrectomy
<b>SHBG</b>	Sex Hormone Binding Globulin
<b>TPN</b>	Total parenteral nutrition
<b>UGI</b>	Upper Gastro-intestinal
<b>VBG</b>	Vertical banded gastroplasty
<b>VMN</b>	Ventromedial nuclei
<b>WHR</b>	Waist/hip circumference ratio
<b>WtHR</b>	Waist to Height Ratio

## ***List of Figures***

<b>Figure</b>	<b>Title</b>	<b>Page</b>
<b>1</b>	Biliopancreatic diversion	66
<b>2</b>	Jejunioileal bypass	68
<b>3</b>	Adjustable gastric banding	70
<b>4</b>	Vertical banded gastroplasty	73
<b>5</b>	Roux-en-Y gastric bypass	77
<b>6</b>	The duodenal switch procedure as performed at the University of Southern California for the treatment of morbid obesity	81
<b>7</b>	Mini-gastric bypass	85
<b>8</b>	Biliopancreatic diversion with duodenal switch	94
<b>9</b>	Sleeve gastrectomy	94
<b>10</b>	Supine split-leg position, also called French position	97
<b>11</b>	Standard trocar placement	98
<b>12</b>	Exposure of the entire stomach and start dissection of the greater curvature	99
<b>13</b>	The greater curvature dissection continues cephalad to the angle of His	100
<b>14</b>	Division of the short gastric vessels is performed up to the fundus using the ultrasonic shears	101

<b>Figure</b>	<b>Title</b>	<b>Page</b>
<b>15</b>	The greater curvature dissection continues from the midpoint distally to approximately 2 cm proximal to the pylorus	102
<b>16</b>	The SG is begun with (a green cartridge) sequential firings of 60-mm/4.8-mm linear staplers reinforced with buttress bioabsorbable material	103
<b>17</b>	The first stapler was positioned so that a narrow 1.5 cm of anterior stomach serosa is visible between the stapler and the lesser curvature	104
<b>18</b>	Normal image of the stomach after laparoscopic sleeve gastrectomy	135
<b>19</b>	Leak following laparoscopic sleeve gastrectomy	135
<b>20</b>	Upper gastrointestinal contrast study showing no flow of contrast into the duodenum and marked dilation of the proximal aspect of the gastric sleeve	142
<b>21</b>	Mechanism of mixed rotation of the stomach about its long axis	144
<b>22</b>	Contrast swallow showing gastric left upper quadrant fistula after sleeve gastrectomy	147
<b>23</b>	CT scan showing collection due to a sleeve gastrectomy leak	147

<b>Figure</b>	<b>Title</b>	<b>Page</b>
<b>24</b>	Endoluminal stent graft therapy	151
<b>25</b>	Management algorithm for sleeve gastrectomy leaks	154
<b>26</b>	Subsequent issues in the management of sleeve gastrectomy leaks	155
<b>27</b>	Stent placement	162
<b>28</b>	Abscess drainage	164



## Introduction

Obesity is originally derived from Latin word (obesus) i.e. to overeat. The modern definition is "a disease of excess body fat" (**Kral, 2001**).

The most widely accepted measure of obesity is the body mass index (BMI) which equals patient weight in kilograms divided by the square of his or her height in meters, a normal BMI ranges from 18.5-24.5 kg/m<sup>2</sup>, overweight equals BMI between 25-29.5 kg/m<sup>2</sup>, obesity equals BMI 30 kg/m<sup>2</sup> or higher (**Herron, 2004**).

Severe obesity is having a BMI greater than 35 kg/m<sup>2</sup>, and morbid obesity is having a BMI greater than 40 kg/m<sup>2</sup> or a BMI greater than 35 kg/m<sup>2</sup> with concomitant obesity-related morbidity (**Brunicardi et al., 2001**).

The patient is considered superobese with a BMI more than 50 kg/m<sup>2</sup> and super-super obese with a BMI more than 60 kg/m<sup>2</sup> (**Ballantyne et al., 2004**).

Morbid obesity is associated with progressive, serious and debilitating co-morbidities such as type II diabetes mellitus, hypertension, hyperlipidaemia, accelerated atherosclerosis, debilitating arthritis of weight-bearing joints, hypoventilation, sleep apnea syndrome,

gastroesophageal reflux disease, infertility & urinary stress incontinence in females, certain cancers, immobility, psychological & economic problems (**Pontiroli et al., 2005**).

There are great effects of weight loss on associated weight-related co-morbidities. Several well-designed studies have shown that type II diabetes mellitus resolves in about 90% of patients, hypertension disappears in two thirds of patients, serum concentration of high density lipoprotein improves, serum cholesterol and triglycerides decrease, many cardiovascular parameters improve as well including left ventricular wall thickness and left ventricular function, concomitantly pulmonary function and musculoskeletal disability improve in concern with the weight loss. Symptomatic obstructive sleep apnea disappears with early weight loss as little as 15-20 kg (**Balsiger et al., 2000**).

Treatment possibilities of obesity include diet restriction, behavioral therapy, medical treatment, and surgery. All non surgical treatment regimens have an extremely high rate of failure and surgery is therefore today is the option for treatment of morbid obesity (**Pontiroli et al., 2005**).

However, serious complications can occur and therefore a careful selection of patients is of utmost importance. Bariatric surgery should at least be considered for all patients with a BMI of more than 40 kg/m<sup>2</sup> and for those with a BMI of more than 35 kg/m<sup>2</sup> with concomitant obesity-related conditions after failure of conventional treatment (**Bult et al., 2008**).

At the present time a number of different surgical procedures are available for treatment of severely obese patients. These procedures create weight loss by two mechanisms of action: restriction and malabsorption (**Herron, 2004**).

The sleeve gastrectomy is a restrictive intervention consisting of a vertical gastrectomy including the entire greater curvature of the stomach while leaving in place an approximately 100-ml gastric tube along the lesser curvature. This intervention was initially proposed as the first part of a duodenal switch in patients whose body mass index was greater than 60 kg/m<sup>2</sup>. Since then, these indications have developed and this intervention now enjoys certain favor on the part of bariatric surgery teams (**Mognol & Marmuse, 2007**).

The Laparoscopic Sleeve Gastrectomy (LSG) has increased in popularity and is currently very "trendy" among laparoscopic surgeons involved in bariatric surgery. As LSG proved to be effective in achieving considerable weight loss in the short-term, it has been proposed by some as a sole bariatric procedure (**Iannelli et al., 2008**).

Management of leaks after LSG can be challenging. Early diagnosis and treatment is important in the management of a leak. However, it can be treated safely via various management options depending on the time of diagnosis and size of the leak (**Rena et al., 2014**).

Laparoscopic sleeve gastrectomy is a new and effective procedure for the surgical management of morbid obesity. Therefore, the number of patients undergoing this procedure will continue to rise. Basic understanding of common complications and available treatment options is essential for all practising general surgeons. By early diagnosis and treatment of these complications, patient morbidity and mortality might be reduced (**Sarkhosh, 2013**).

## **Aim of Work**

To review the literature regarding recent updates in medical and surgical management of morbid obesity, with focus on sleeve gastrectomy in treatment of morbid obesity and its effect, advantages and complications.

## Definition and Diagnosis

### ***Definition:***

Obesity is a term used to describe body weight that is much greater than what is healthy. If you are obese, you also have a much higher amount of body fat than is healthy or desirable (**Kaplan et al., 2007**).

Adults with a *body mass index* (BMI, calculated as weight in kilograms divided by height in meters squared) between 25 kg/m<sup>2</sup> and 30 kg/m<sup>2</sup> are considered overweight. Adults with a BMI greater than or equal to 30 kg/m<sup>2</sup> are considered obese. Anyone who is more than 100 pounds overweight or who has a BMI greater than or equal to 40 kg/m<sup>2</sup> is considered morbidly obese (**Leslie et al., 2007**).

Obesity has been associated with an increased hazard ratio for all-cause mortality, as well as significant medical and psychological co morbidity (**Berrington et al., 2010**).

Obesity is a risk factor for many diseases, including diabetes and cardiovascular disease. It results in a higher risk of hospitalization and mortality; morbidity equal to that attributable to poverty, smoking, and problem drinking; and substantial health care expenditures. It is a growing epidemic worldwide and the second leading cause of

preventable death in developing countries (**Bardia et al., 2007**).

Indeed, obesity is not only a chronic medical condition but should be regarded as a bona fide disease state (**Mechanick et al., 2012**).

***Causes, incidence, and risk factors:***

Obesity is caused by a complex interaction of environmental factors, human behaviour and genetic predisposition, and it is associated with high mortality and risk of various chronic diseases. The distribution of adiposity has more influence on outcomes than the total amount of body fat; in particular, an android pattern of fat mass is associated with an increased risk of metabolism-related disorders. The location of fat (visceral or subcutaneous) also has different effects on the development and pathogenesis of metabolic and cardiovascular diseases, with increased visceral fat being associated with an adverse metabolic profile (**Livingston, 2012**).

Taking in more calories than you burn leads to being overweight and, eventually, obesity. The body stores unused calories as fat. Obesity can be the result of:

- Eating more food than your body can use.